– K-CAB approved by MFDS last July as Korea’s 30th home grown novel drug, a P-CAB type gastro esophageal reflux disease treatment.
– Quick drug efficacy and night time inhibition of gastric acid secretion properties expected to overtake gastroesophageal reflux disease market
February 25th, CJ Healthcare CEO Seok-Hee Kang announced the hosting of the K-CAB Tab launching symposium at the Shilla Hotel, Seoul on the 24th of February.
CJ Healthcare’s gastro esophageal reflux disease treatment drug K-CAB is a novel drug with a new mechanism of action(P-CAB), gaining approval by the MFDS last July as Korea’s 30th home grown novel drug . K-CAB is currently in the process of setting its selling price.
The symposium was held with the purpose to show human trial data between K-CAB, a P-CAB classified drug, with existing PPI drugs and to share recent advances on gastroesophageal reflux disease. Over 800 professionals from the medical field attended the symposium.
The symposium consisted of two sessions with Professor Kim Na-Young of Seoul National University, Professor Jung Hoon-Yong of Ulsan University, and Professor Lee Kwang-Jae of Ajou University School of Medicine concluding the symposium with a panel discussion on diagnosis and treatment on gastroesophageal reflux disease.
Professor Sang Woo Lee(Korea Univ.) and Professor Su Hun Park(Catholitc Medical Univ.) acted as facilitators for the first session where Professor In Jin Chang of Seoul National Univ. made his presentation on ‘Mechanisms of Gastric Acid Secretion: Novel P-CAB’ and Professor Jun Haeng Lee of Seunkyunkwang Univ. making is presentation on ‘PPI vs. K-CAB’.
Professor In Jin Chang stated “K-CAB tablets is a new gastric acid secretion inhibitor that has a different chemical structure and a different mechanism of action to the conventional PPIs. K-CAB, based on quick drug efficacy does not affect daily eating habits and has minimal side effects, overcoming the main disadvantages of the PPIs.
Professor Jun Haeng Lee showed high hopes for K-CAB as the drug that will shift the paradigm in gastro esophageal reflux disease treatment market and quoted that “PPIs, when taken twice a day(day and night) showed nocturnal acid breakthrough symptoms starting from 1:00am and lasting for over 1 hour with pH levels less than 4, while a tablet of K-CAB per day, showed inhibition of nocturnal acid by maintaining pH level of 4 for 24 hours while showing stability throughout the same period.”
Prof. Poong Yeol Lee of Seungkyunkwan Unvi. and Prof. Oh Young Lee of Hanyang Medical school acted as facilitators of the second session while Prof. Suk Chae Choi of Wonkwang medical school made his presentation of ‘GERD unmet needs and role of Tegoprazan’.
Prof. Choi stated that “K-CAB tablets showed gastric acid secretion inhibition on the first day of intake. Not only does it improve the lives of patients who have no reaction to the conventional PPI products but, will become to be drug that modifies the fundamental process and pattern of gastric acid secretion.
Prof. George Sachs of UCLA, who is well known for his findings on proton pump mechanisms and his research work on PPIs, introduced K-CAB as the next generation drug at the Asian Pacific Digestive Week 2018.
CJ HealthCare’s CEO Seok Hee Kang quoted “The first P-CAB type drug developed in Korea, K-CAB, is targeted not only to grow as a global power house drug but to improve the lives of people with gastro esophageal reflux disease.
K-CAB was approved in July for the first time as the world’s first P-CAB-based drug for both ERD(erosive gastroesophageal reflux disease) and NERD(non-erosive astroesophageal reflux disease) and is in the process of setting its selling price. CJ Healthcare and Chong Kun Dang recently signed a joint sales and marketing contract.